Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Obama to Announce Plan to Respond to Bioterrorism

By Drug Discovery Trends Editor | January 26, 2010

WASHINGTON (AP) – President Barack Obama will use his State of the Union address to unveil a new plan for a better and quicker response to bioterrorism threats and attacks, the White House said January 26.

The announcement came just hours after the release of a report critical of the government’s ability to prepare and respond to bioterrorist attacks.

Obama will be asking government leaders to rethink their plans for medical countermeasures so that quick, reliable and affordable antidotes will be available during any public health emergency, White House spokesman Nick Shapiro said. This would be a redesign of the medical antidote system, he said.

Earlier Tuesday, the Commission on the Prevention of Weapons of Mass Destruction Proliferation gave the Obama administration a failing grade for its efforts to prepare for and respond to a biological attack.

In 2008, the WMD was also critical of the government’s ability to prepare and respond to a biological attack. The government did respond to that and developed a plan to prevent the illegal spread of biological weapons, such as anthrax. Obama rolled out that plan in November.

A month later, Obama signed an order to create a system so that the federal government could rapidly distribute medical countermeasures to supplement state and local responses after a biological attack, Shapiro said. The system relies partly on the U.S. Postal Service’s ability to reach every American household.

Obama new plan will mean that better and cheaper drugs will be distributed more quickly, he said.

Despite these efforts, the WMD commission said the Obama administration is not addressing urgent threats, including bioterrorism.

“Each of the last three administrations has been slow to recognize and respond to the biothreat,” said former Sen. Bob Graham, chairman of the commission. “But we no longer have the luxury of a slow learning curve, when we know al-Qaida is interested in bioweapons.”

Retired Air Force Col. Randy Larsen, the commission’s executive director, said the government was poorly prepared for the swine flu epidemic in 2009, suggesting that the country is not positioned to respond to something more serious. He pointed to the early shortage of H1N1 vaccine despite a six-month warning from health officials that the disease would be potentially deadly.

The shortage, however, was largely due to private manufacturing problems that the government hopes to alleviate in the future with a different process to make flu vaccine. The government’s work to identify the new flu virus and create seed stock for a vaccine quickly has been praised.

The WMD commission was formed by Congress to evaluate the government’s readiness for a terror attack involving weapons of mass destruction.

Its report follows a study released Monday that warned that al-Qaida is still pursuing technology to conduct a biological, chemical or even nuclear attack against the United States.

That study, released by Harvard University’s Belfer Center for Science and International Affairs, said al-Qaida’s “top WMD priority has been to acquire nuclear and strategic biological weapons.”

Date: January 26, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50